Compounds / Longevity / Follistatin 344

Follistatin 344

Follistatin 344 (Myostatin Inhibitor — TGF-β Antagonist)
LongevityEmerging ResearchFDA: Not approved; gene therapy trials for...WADA: PROHIBITED — Category S2

Overview

Significant interest for muscle building and dystrophy research. Inhaled AAV-Follistatin 344 gene therapy trials for Duchenne. Protein injection research ongoing.

Mechanism of Action

Binds and neutralizes myostatin (GDF-8) and activin A. Myostatin inhibition removes brake on muscle growth. Activates satellite cells. Studied for muscular dystrophy and muscle wasting conditions.

Pharmacokinetics

Half-life
1.5 hrs
Peak (Tmax)
9 min
Cleared
~7.5 hrs

Molecular Profile

Molecular weight
~31,500 Da
Type
Glycoprotein with follistatin domains
Length
344 amino acids

Key Research Findings

Myostatin inhibition; activin A blockade; satellite cell activation; muscular dystrophy research.

Published Research

J Cell Physiol (2009)
Rodino-Klapac LR et al. Inhibition of myostatin with emphasis on follistatin
View source

Related Longevity Compounds

GHK-CuEpithalonMOTS-cSS-31FOXO4-DRINAD+
Clinical Guidance

Research data is not a treatment plan. If you are considering Follistatin 344, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.
Running Follistatin 344? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator  ·  Full deep dive  ·  Peptide fundamentals